• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Cardiology

Gantenerumab does not slow cognitive decline in early Alzheimer’s

byJunghoon KoandKiera Liblik
November 23, 2023
in Cardiology, Neurology
Reading Time: 3 mins read
Alzheimer's disease collage: a calm older woman in a cardigan beside a speckled brain drawing and three puzzle pieces
Share on FacebookShare on TwitterShare on LinkedIn

1. In these two randomized parallel-group trials, the use of gantenerumab did not lead to slower cognitive decline over 116 weeks among persons with early symptomatic Alzheimer’s disease compared to placebo.

2. After 116 weeks, gantenerumab was associated with lower amyloid plaque burden than the placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The accumulation of aggregated amyloid-beta (Aβ) has been posited to play a significant role in the pathologic processes of Alzheimer’s disease. Monoclonal antibodies which target Aβ proteins have been developed but their efficacy in clinical trials has been equivocal. Gantenerumab, a human anti-Aβ IgG1 monoclonal antibody that removes Aβ via microglia-mediated phagocytosis, has been shown to have effects on biomarkers of Alzheimer’s disease and neurodegeneration. These two phase III trials aimed to determine the clinical and biological effects and safety of gantenerumab in the treatment of persons with early symptomatic Alzheimer’s disease. Overall, the studies showed there was no significant difference in clinical decline in the gantenerumab group versus the placebo group. The use of gantenerumab was associated with lower amyloid plaque burden, although the magnitude of plaque removal was less than expected based on previous studies. The generalizability of the findings in these trials is limited due to the lack of racial diversity in the trial population and comparisons between these trials and previous trials involving anti-amyloid antibodies are also limited due to significant differences in protocol.

Click to read the study in the NEJM (New England Journal of Medicine)

Relevant Reading: Lecanemab in Early Alzheimer’s Disease

RELATED REPORTS

Earlier menopause is associated with faster cognitive decline and greater late-life brain changes

Older married couples demonstrate domain-specific cognitive concordance 

In-Depth [randomized controlled trial]: GRADUATE I and II were phase III, randomized, parallel-group trials that investigated the efficacy of gantenerumab in the treatment of early symptomatic Alzheimer’s disease. Persons 50 to 90 years of age with a Clinical Dementia Rating – Global Score (CDR-GS) of 0.5 or 1 and evidence of amyloid plaques on positron-emission tomography or cerebrospinal fluid (testing were selected, and excluded if they had other clinically significant findings on magnetic resonance imaging (MRI) which could cause cognitive impairment. Participants were randomly assigned in a 1:1 ratio to receive gantenerumab or placebo for 116 weeks and gantenerumab was administered at a prespecified dosing schedule. Participants also underwent regular MRI for assessment of amyloid-related imaging abnormalities (ARIA). The primary outcome was defined as the change in baseline in the score of the CDR-Sum of Boxes (CDR-SB) at week 116, with higher scores indicative of greater cognitive impairment. In total, 985 and 980 participants were enrolled in GRADUATE I and GRADUATE II respectively. In GRADUATE I, the primary outcome was 3.35 and 3.65 in the gantenerumab and placebo groups respectively (difference, -0.31; 95% Confidence Interval [CI], -0.66 to 0.05; p=0.10). In GRADUATE II, the primary outcome was 2.82 and 3.01 in the gantenerumab and placebo groups (difference, -0.19; 95% CI, -0.55 to 0.17; p=0.30). The difference in the adjusted mean (+/- standard error) amyloid level between the gantenerumab and placebo groups was -66.44 +/- 4.17 centiloids (95% CI, -74.71 to -58.16) and 56.46 +/- 3.98 centiloids (95% CI, -64.36 to -48.56) in GRADUATE I and GRADAUTE II, respectively. In summary, these trials demonstrated the use of gantenerumab in persons with early symptomatic Alzheimer’s disease was not associated with slower clinical decline at week 116.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Alzheimer'sAlzheimer’s diseaseamyloid plaquechronic diseasecognitive declineEarly alzheimer'sGantenerumabneurology
Previous Post

Mastering Lineweaver-Burk Plots: A Comprehensive Guide for MCAT Biochemistry

Next Post

#VisualAbstract: Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis

RelatedReports

An illustration showing a brain scan alongside a human brain, symbolizing brain health and cognitive decline.
Longevity

Earlier menopause is associated with faster cognitive decline and greater late-life brain changes

October 5, 2026
Brain health collage: an engraved brain in side view, a branching neuron, a plain brain-slice silhouette and a reflex hammer
Neurology

Older married couples demonstrate domain-specific cognitive concordance 

August 28, 2026
Brain health collage: an engraved brain in side view, a branching neuron, a plain brain-slice silhouette and a reflex hammer
Chronic Disease

One in four National Football League (NFL) players who died between 2016-2021 had evidence of chronic traumatic encephalopathy

August 27, 2026
Brain health collage: an engraved brain in side view, a branching neuron, a plain brain-slice silhouette and a reflex hammer
Chronic Disease

Brain-predicted age difference may reliably predict dementia progression

August 19, 2026
Next Post
#VisualAbstract: Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis

#VisualAbstract: Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis

Teixobactin appears to avoid bacteria resistance [PreClinical]

Decolonization reduces hospitalization rates in nursing home residents

Exercise collage: a smiling older man with a towel over his shoulder, a kettlebell, a running shoe and a resistance band

Home-based exercise program effective for improving outcomes in patients with patellofemoral pain

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Removing Race and Ethnicity From Dialysis Mortality Risk Adjustment Changes Facility Performance Rankings
  • AI Model Shows Promise in Predicting PTSD Risk Following Trauma
  • 2 Minute Medicine Rewind November 16, 2026
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.